Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Clinical trial NCT03935347 · WITHDRAWN

Trial details

NCT number: NCT03935347
Sponsor: Roswell Park Cancer Institute
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Bladder Urothelial Carcinoma Metastatic Renal Pelvis Urothelial Carcinoma Metastatic Ureter Urothelial Carcinoma Metastatic Urethral Urothelial Carcinoma Unresectable Renal Pelvis Urothelial Carcinoma Unresectable Ureter Urothelial Carcinoma

Start date: 2019-06-20
Primary completion: 2022-05-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.